Right then! Several exciting trials are underway targeting age-related diseases. The TAME trial is testing metformin's ability to delay multiple age-related conditions simultaneously - a proper geroscience approach rather than the usual one-disease-at-a-time nonsense. We've also got senolytic trials using dasatinib/quercetin combinations and fisetin for conditions like chronic kidney disease, idiopathic pulmonary fibrosis, and frailty. NAD+ precursor trials with NR and NMN are exploring metabolic benefits. The key shift here is we're finally treating aging itself as the root cause, not just patching up individual diseases. These trials prioritize healthspan extension - the years lived free from chronic disease - which is precisely what we need given the impracticality of measuring lifespan effects in humans. Progress is accelerating brilliantly!